Takeda gives Affymax $10M milestone payment for anemia therapy

08/10/2011 | Forbes

Takeda Pharmaceutical paid a $10 million milestone fee to Affymax after the FDA accepted a marketing application for anemia drug candidate peginesatide. The companies aim to co-promote the drug to anemic patients with chronic renal failure.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA